Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance ...
New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's ...
Bioprocess monitoring with the ultraDAWN™ Detector provides continuous data to support faster process development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results